Last reviewed · How we verify

NCT03353363

Wound Infiltration of Liposomal Bupivacaine v Plain Bupivacaine for Post-Op Pain Control in Elective Cesarean Delivery

Status unknown Phase 4 Last updated 18 January 2018
What this trial tests

Phase 4 trial testing Bupivacaine in Bupivacaine in 132 participants. Status unknown.

Timeline
18 October 2017
Primary endpoint
18 October 2018
18 February 2019

Quick facts

Lead sponsorBrooke Army Medical Center
PhasePhase 4
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingtriple
Primary purposetreatment
Enrollment132
Start date18 October 2017
Primary completion18 October 2018
Estimated completion18 February 2019
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Brooke Army Medical Center

Who can join

18 and older, female only, with Bupivacaine or Pain, Postoperative. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Randomized double blind placebo controlled trial to compare the post-operative pain control advantages of post-incisional wound infiltration with liposomal bupivacaine to plain bupivacaine in patients presenting for elective caesarean delivery.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Bupivacaine

Trials testing the same drug.

Other recruiting trials for Bupivacaine

Currently open trials in the same condition.

Other Brooke Army Medical Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03353363.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing